Free Trial
→ The mainstream media is wrong about AI — again (From Weiss Ratings) (Ad)
OTCMKTS:MCUJF

Medicure 11/25/2024 Earnings Report

Medicure logo
$0.83 -0.03 (-3.84%)
As of 06/13/2025 01:30 PM Eastern
ProfileEarnings History

Medicure EPS Results

Actual EPS
$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Date
11/25/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Medicure Earnings Headlines

Medicure reports stable intangible assets in Q1 filing
May 23, 2025 | investing.com
Medicure Inc. (MCUJF) Q4 2024 Earnings Call Transcript
April 30, 2025 | seekingalpha.com
Nvidia’s Huang: AI is going to need 100x more power
Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires "100 times more" power. Chip giant AMD's Chief Executive Lisa Su agrees. She declared that the need for more power is already "orders of magnitude higher" than just last year.
June 16, 2025 | Weiss Ratings (Ad)
Medicure Inc. Reports 2024 Financial Results with Increased Revenue but Net Loss
April 25, 2025 | tipranks.com
Medicure Expands U.S. Pharmacy Business with West Olympia Acquisition
April 11, 2025 | tipranks.com
Medicure Completes Strategic Acquisition of Gateway Medical Pharmacy
March 11, 2025 | tipranks.com
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF), a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

View Medicure Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles